ASX:EX1Exopharm Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Exopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.21 0.00 (0.00 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.21Now: A$0.21▼A$0.2150-Day RangeA$0.21MA: A$0.21▼A$0.2152-Week RangeA$0.15Now: A$0.21▼A$0.48VolumeN/AAverage VolumeN/AMarket Capitalization$20.05 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlines Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing clinical human therapeutics in Australia. It is developing Plexaris, an exosome derived from human platelets; and Exomeres, an exosome derived from adult stem cells. The company was founded in 2003 and is headquartered in Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Exopharm. Previous Next 2.9 Community Rank Outperform VotesExopharm has received 8 “outperform” votes. (Add your “outperform” vote.)Underperform VotesExopharm has received 6 “underperform” votes. (Add your “underperform” vote.)Community SentimentExopharm has received 57.14% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Exopharm and other stocks. Vote “Outperform” if you believe EX1 will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EX1 will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldExopharm does not currently pay a dividend.Dividend GrowthExopharm does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exopharm insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Exopharm is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exopharm is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExopharm has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.58 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:EX1 Previous Symbol CUSIPN/A CIKN/A Webwww.exopharm.com Phone61 3 9111 0026Debt Debt-to-Equity Ratio0.10 Current Ratio8.60 Quick Ratio8.34Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$38,871.00 Price / Sales515.79 Cash FlowA$0.06 per share Price / Cash Flow3.39 Book ValueA$0.07 per share Price / Book3.04Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares95,472,000Market Cap$20.05 million Next Earnings DateN/A OptionableNot Optionable Receive EX1 News and Ratings via Email Sign-up to receive the latest news and ratings for EX1 and its competitors with MarketBeat's FREE daily newsletter. Exopharm (ASX:EX1) Frequently Asked Questions How has Exopharm's stock been impacted by COVID-19 (Coronavirus)? Exopharm's stock was trading at A$0.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EX1 shares have decreased by 2.3% and is now trading at A$0.21. View which stocks have been most impacted by Coronavirus. Has Exopharm been receiving favorable news coverage? Headlines about EX1 stock have trended somewhat negative on Saturday, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Exopharm earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Exopharm. Who are some of Exopharm's key competitors? Some companies that are related to Exopharm include Novoheart (NVH), Biopharmx (BPMX), Omega Diagnostics Group (ORPH), Orthocell (OCC), Cynata Therapeutics (CYP), Pediapharm (PDP), Biotron (BIT), Cohbar (CWBR), Promis Neurosciences (PMN), Sirona Biochem (SBM), Immutep (IMM), e-Therapeutics (ETX), Oxford Biodynamics (OBD), Navidea Biopharmaceuticals (NAVB) and Synairgen (SNG). View all competitors. Who are Exopharm's key executives? Exopharm's management team includes the following people: Dr. Ian Dixon MBA, Ph.D., Company Founder, Technology Co-Founder, MD & DirectorDr. Gregor Lichtfuss, COO & Technology Co-FounderMr. David Rodney Parker B.Com, SAFin, ACIS, Non-Exec. Director & Company Sec. (Age 40) What is Exopharm's stock symbol? Exopharm trades on the ASX under the ticker symbol "EX1." What is Exopharm's stock price today? One share of EX1 stock can currently be purchased for approximately A$0.21. How big of a company is Exopharm? Exopharm has a market capitalization of $20.05 million and generates $38,871.00 in revenue each year. What is Exopharm's official website? The official website for Exopharm is www.exopharm.com. How can I contact Exopharm? The company can be reached via phone at 61 3 9111 0026. This page was last updated on 7/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
